Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -160.93% | 1.93% | -90.76% | 39.60% | 181.43% |
| Total Depreciation and Amortization | -27.42% | -9.05% | -25.64% | -25.42% | -30.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.33% | 5.79% | 103.98% | -43.47% | -59.55% |
| Change in Net Operating Assets | 89.34% | 81.67% | -21.43% | 106.63% | -27.96% |
| Cash from Operations | -160.80% | 62.17% | 106.36% | 66.62% | 176.37% |
| Capital Expenditure | -- | 67.78% | 93.80% | -82.83% | 45.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 301.11% | -100.01% | -113.90% | 45.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -63.73% | 628.67% | -99.64% | -- | -93.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.73% | 628.67% | 100.06% | -- | -93.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.79% | 94.97% | 151.25% | 65.02% | 269.67% |